Clicky

EyePoint Pharmaceuticals, Inc.(EYPT) News

Date Title
Sep 4 EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
Aug 27 EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Jul 15 Milestone Pharmaceuticals Refreshes Board of Directors
Jun 26 EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
May 17 Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
May 10 EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
May 8 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
May 6 Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
May 6 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
Apr 2 EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
Mar 9 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%
Mar 8 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
Mar 8 EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Mar 8 Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call
Mar 7 EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023
Mar 7 Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
Mar 7 EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
Mar 4 EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
Feb 3 EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Jan 14 EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 71% Above Its Share Price